Trial · NCT03175367
Results by group81
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 81
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | -50.6 | Standard Error 5.2 | Percent Change | |
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | -1.1 | Standard Error 5.8 | Percent Change | |
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -24.8 | Standard Error 5.7 | Percent Change | |
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -52.0 | Standard Error 5.3 | Percent Change | |
| Percent Change From Baseline in Non-HDL-C at Week 24 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 10.4 | Standard Error 7.0 | Percent Change | |
| Percent Change From Baseline in Non-HDL-C at Week 24 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -20.2 | Standard Error 6.7 | Percent Change | |
| Percent Change From Baseline in Non-HDL-C at Week 24 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -44.3 | Standard Error 6.4 | Percent Change | |
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Placebo SC QW (DBTP) | 11.3 | Percentage of Participants | ||
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 68.1 | Percentage of Participants | ||
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | 73.9 | Percentage of Participants | ||
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | 71.4 | Percentage of Participants | ||
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 15.5 | Percentage of Participants | ||
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | 57.9 | Percentage of Participants | ||
| Percentage of Participants With >= 30% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | 86.8 | Percentage of Participants | ||
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Placebo SC QW (DBTP) | 5.2 | Percentage of Participants | ||
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 28.6 | Percentage of Participants | ||
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | 53.7 | Percentage of Participants | ||
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | 60.6 | Percentage of Participants | ||
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 12.3 | Percentage of Participants | ||
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | 24.6 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03175367/results?page=2